We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Results 1 to 5 of 40
Most popular |Most recent

In Mayo, Federal Circuit Seeks to Head Off Disputes Over When Claims Are “Deemed Allowable” by Counting Continued Examination Time Until Notice of Allowance

USA - September 19 2019 Earlier this week, the Federal Circuit declined to further extend the patent term of an antibody patent held by the Mayo Foundation. In Mayo...

Benjamin F. Jackson.

Federal Circuit Walks Back Its “Exceptional” Stance on the Doctrine of Equivalents in the Latest Amgen v. Sandoz Decision

USA - September 6 2019 In Amgen’s long-running dispute with biosimilar-maker Sandoz over biosimilar versions of Amgen’s filgrastim (Neupogen) and pegfilgrastim (Neulasta)...

Andrew D. Cohen, Jay J. Cho.

Amgen Files New Patent Infringement Suit Over Neupogen Biosimilar

USA - August 5 2019 On July 23, 2019, Amgen, maker of the cancer treatment drug Neupogen (filgrastim), filed patent infringement claims in the Southern District of...

Michael Fresco.

Prosecution History Estoppel Bars Amgen’s Doctrine-of-Equivalents Infringement Claim Against Neulasta (Pegfilgrastim) Biosimilar Maker Coherus

USA - July 31 2019 Amgen Inc. v. Coherus Biosciences Inc., No. 2018-1993, Slip op. at 6 (Fed. Cir. July 29, 2019) stems from a Biologics Price Competition and Innovation...

Jay J. Cho.

Q2 2019 Review: Biosimilar IPRs See a Drop in New Filings and Mixed Results

USA - July 24 2019 At the end of 2017, inter partes review (IPR) proceedings for biosimilar products were on the rise. 2018 and the first half of 2019, however, have...

Aron Fischer, Zhiqiang Liu.